TrophiPatch™
Chronic skin ulcers (e.g., Diabetic Foot Ulcers)
Phase 1Active
Key Facts
About HekeTiss
HekeTiss is a private, pre-revenue biotech company developing an innovative cell therapy for chronic wounds, a major unmet need affecting over 1% of the global population. Its core technology involves functionally enhancing adipose-derived stem cells to create TrophiPatch™, a bioresorbable cellular sponge currently in first-in-human clinical studies. The company, led by its scientific founders and supported by Swiss innovation grants, aims to provide an effective, off-the-shelf solution to transform the standard of care in wound management.
View full company profile